Clinical bottom line
Targeted therapies, particularly immune checkpoint inhibitors and epidermal growth factor receptor (EGFR) inhibitors, have transformed the management of advanced cutaneous squamous cell carcinoma (cSCC), offering improved response rates and durable disease control. Immune checkpoint blockade shows promise even in immunosuppressed populations, though safety and efficacy require careful balancing. Emerging strategies combining immunomodulation with targeted agents may further enhance outcomes. Despite encouraging advances, heterogeneity in patient response and limited data in special populations highlight the need for personalized approaches and ongoing research (Pabianek et al., 2025; Petty et al., 2026).
What the evidence shows
Pabianek et al. (2025) provide a comprehensive narrative review on immune checkpoint blockade in advanced cSCC, emphasizing its efficacy in immunosuppressed patients, including transplant recipients and those with hereditary syndromes. They report meaningful tumor regression and prolonged survival, albeit with increased risk of immune-related adverse events necessitating vigilant monitoring.
Petty et al. (2026) summarize recent advances in targeted and immunotherapies for high-risk cutaneous malignancies, highlighting the role of programmed death-1 (PD-1) inhibitors as first-line systemic treatment for unresectable or metastatic cSCC. They discuss ongoing trials exploring combination regimens and novel targets to overcome resistance.
He et al. (2020) focus on EGFR and regulatory T cell (Treg) targeted therapies, outlining their mechanistic rationale and potential synergy. EGFR inhibitors have demonstrated clinical activity in cSCC, particularly in patients unsuitable for immunotherapy, though responses are often less durable.
Nahm et al. (2025) review abscopal effects and immunomodulation in skin cancer therapy, suggesting that combining radiotherapy with immune checkpoint inhibitors may potentiate systemic anti-tumor immunity in cSCC.
Mavropoulos et al. (2014) discuss prospects for personalized targeted therapies, advocating biomarker-driven treatment selection to optimize efficacy and minimize toxicity.
Caveats and uncertainty
Most clinical data derive from single-arm trials or retrospective series, with limited randomized controlled trial evidence.
Immunosuppressed patients remain underrepresented in clinical trials, complicating risk-benefit assessment.
Immune-related adverse events can be severe and may limit therapy continuation.
Resistance mechanisms to targeted agents are incompletely understood.
Biomarkers predictive of response and toxicity require validation.
Cost and access to novel agents may restrict widespread implementation.
How this may change practice
Clinicians should consider immune checkpoint inhibitors as standard systemic therapy for advanced cSCC, including in select immunosuppressed patients after multidisciplinary evaluation.
EGFR inhibitors remain an option for patients contraindicated for immunotherapy or with refractory disease.
Integration of combination approaches, such as immunotherapy plus radiotherapy, may improve outcomes in future.
Personalized treatment guided by molecular and immune profiling may optimize patient selection.
Enhanced monitoring and management protocols for immune-related toxicities are essential.
Ongoing clinical trials will inform evolving standards and expand therapeutic options.